Elena Martinez-Terroba

Elena Martinez-Terroba

Auto-generated profile, based on publicly available information

Elena Martinez-Terroba

Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2024 in Science Immunology
Verified
Journal Article
Closed access
EMElena Martinez-Terroba
Elena Martinez-Terroba
LPLeah M. Plasek-Hegde
Leah M. Plasek-Hegde
ICIoannis Chiotakakos
Ioannis Chiotakakos
VLVincent Li
Vincent Li
FMFernando J. de Miguel
Fernando J. de Miguel
NDNadya Dimitrova
Nadya Dimitrova
Expression of the long noncoding RNA (lncRNA) metastasis–associated lung adenocarcinoma transcript 1 ( MALAT1 ) correlates with tumor progression and metastasis in many tumor types. However, the impact and mechanism of action by which MALAT1 promotes metastatic disease remain elusive. Here, we used CRISPR activation (CRISPRa) to overexpress MALAT1/Malat1 in patient-derived lung adenocarcinoma (LUAD) cell lines and in the autochthonous K-ras/p53 LUAD mouse model. Malat1 overexpression was sufficient to promote the progression of LUAD to metastatic disease in mice. Overexpression of MALAT1/Malat1 enhanced cell mobility and promoted the recruitment of protumorigenic macrophages to the tumor microenvironment through paracrine secretion of CCL2/Ccl2. Ccl2 up-regulation was the result of increased global chromatin accessibility upon Malat1 overexpression. Macrophage depletion and Ccl2 blockade counteracted the effects of Malat1 overexpression. These data demonstrate that a single lncRNA can drive LUAD metastasis through reprogramming of the tumor microenvironment.

15 January 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Mutations within the oncogene KRAS drive an estimated 25% of all cancers. Only allele-specific KRAS G12C inhibitors are currently available and are associated with the emergence of acquired resistance, partly due to upstream pathway reactivation. Given its upstream role in the activation of KRAS, son of sevenless homolog 1 (SOS1), has emerged as an attractive therapeutic target. Agents that target SOS1 for degradation could represent a potential pan-KRAS modality that may be capable of circumventing certain acquired resistance mechanisms. Here, we report the development of two SOS1 cereblon-based bifunctional degraders, BTX-6654 and BTX-7312, cereblon-based bifunctional SOS1 degraders. Both compounds exhibited potent target-dependent and -specific SOS1 degradation. BTX-6654 and BTX-7312 reduced downstream signaling markers, pERK and pS6, and displayed antiproliferative activity in cells harboring various KRAS mutations. In two KRAS G12C xenograft models, BTX-6654 degraded SOS1 in a dose-dependent manner correlating with tumor growth inhibition, additionally exhibiting synergy with KRAS and MEK inhibitors. Altogether, BTX-6654 provided preclinical proof of concept for single-agent and combination use of bifunctional SOS1 degraders in KRAS-driven cancers.

2 April 2024
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Table S4 displays the IC50 values for BTX-6654 and BTX-7312 from all 3D proliferation assays examined in this study

17 June 2026
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Table S5 shows the IC50 values for SOS1 inhibitors in 3D proliferation assays for KRAS G12D cell lines

17 June 2026
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Table S3 lists the EC50 and IC50 values for ternary complex formation and SOS1 binding for compounds used in this study

17 June 2026
Verified
Other
Open access
KBKyle Begovich
Kyle Begovich
ASAngela Schoolmeesters
Angela Schoolmeesters
NRNavin Rajapakse
Navin Rajapakse
EMElena Martinez-Terroba
Elena Martinez-Terroba
MKManeesh Kumar
Maneesh Kumar
LFLeah Fung
Leah Fung
Supplementary Figure S1 displays the effects of SOS1 degraders on SOS1-complex interactors and neosusbstrates